

**Zetiq receives Israeli Government support for collaboration project with Biomics Biotechnologies of China**

Zetiq Technologies Ltd. ("Zetiq"), a subsidiary of Bio-Light Ltd. (TASE: BOLT) and a developer of early cancer diagnosis tools, announces that it has received confirmation from the Israeli Office of Chief Scientist for receiving a grant from the China Israel Bi-national fund. The grant will be used by Zetiq to expand the collaboration with Biomics Biotechnology of China – a leading biotechnology company focused on the generation of biotechnology products, for developing the CellDetect® cervical cancer identification product, for the Chinese market. Confirmation of the support by the Israeli side of the Bi-national fund advances the confirmation of the support already granted by the Chinese government to Biomics.

Dr. Ami Eyal, Bio-light CEO says: "the unique cervical cancer diagnosis product developed by Zetiq, for which the company issued a CE regulatory mark in Europe, enables to perform identification and diagnosis of cancer cells. The grant from the Israeli Office of Chief Scientist paves the way to complete developing this product for the Chinese market. The prevalence of cervical cancer in the far east is one of the highest in the world, and early detection of the disease reduces by far mortality, nevertheless the current available tools are not accurate enough, and are cumbersome as well as frequently expensive. Zetiq's technology is more effective and reliable, requires less expertise to work with, so that its advantages over current methods is clear".

Dr. Adi Elkeles, Zetiq CEO says: "We appreciate the support of the Israeli Office of Chief Scientist and the grant for the China-Israel Bi-national fund. It is important to stress the significance of this project – the cervical cancer market in China is huge, with an estimated 300 million women in need for periodical examination for early detection of the disease. We are in close and continuous dialog with our colleagues at Biomics Biotechnologies and the working plans are very clear – our joint entry to the Chinese market is an important milestone for Zetiq".

**About Zetiq:**

Zetiq Technologies Ltd. develops effective cancer diagnostic tools. A significant medical need exists for early stage diagnostic tools for screening, monitoring or



diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company's products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:

Dr. Adi Elkeles

CEO

Zetiq Technologies Ltd.

[www.zetiq.co.il](http://www.zetiq.co.il)

[adi@bio-light.co.il](mailto:adi@bio-light.co.il)